Published in Cancer Sci on September 01, 2003
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer (2004) 0.97
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer (2007) 0.92
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. Br J Cancer (2004) 0.85
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. J Immunol Res (2015) 0.81
Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. Br J Cancer (2004) 0.80
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. J Transl Med (2014) 0.80
Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) (2011) 0.78
Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol (2005) 0.78
Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol (2013) 0.77
Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency. Immunology (2013) 0.76
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol (2003) 2.86
Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg (2004) 2.57
Multifunctional Alloys Obtained via a Dislocation-Free Plastic Deformation Mechanism. Science (2003) 2.33
Myocardial velocity gradient as a noninvasively determined index of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 2.05
A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol (2009) 1.99
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res (2006) 1.90
Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology (2013) 1.76
Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol (2003) 1.75
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer (2005) 1.73
Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol (2002) 1.72
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65
EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
Three or more median sternotomies for patients with valve disease: role of computed tomography. Ann Thorac Surg (2003) 1.58
Transient portacaval shunt for a small-for-size graft in living donor liver transplantation. Liver Transpl (2007) 1.57
Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation (2002) 1.57
Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci (2003) 1.56
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer (2002) 1.54
Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Circ J (2010) 1.51
Does intensive management of cerebral hemodynamics and atheromatous aorta reduce stroke after coronary artery surgery? Ann Thorac Surg (2008) 1.50
Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother (2005) 1.47
Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci (2011) 1.43
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci (2006) 1.41
Risk factors for portal vein complications in pediatric living donor liver transplantation. Clin Transplant (2010) 1.39
Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. Am J Kidney Dis (2002) 1.32
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate (2003) 1.32
Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice. J Hepatol (2005) 1.31
Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol (2009) 1.30
She4p/Dim1p interacts with the motor domain of unconventional myosins in the budding yeast, Saccharomyces cerevisiae. Mol Biol Cell (2003) 1.29
Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg (2010) 1.28
The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. Hepatology (2009) 1.26
Alteration of regiospecificity in biphenyl dioxygenase by active-site engineering. J Bacteriol (2002) 1.23
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol (2010) 1.23
Control of intraoperative bleeding during liver resection: analysis of a questionnaire sent to 231 Japanese hospitals. Surg Today (2002) 1.19
Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res (2005) 1.19
Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg (2005) 1.18
Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation (2004) 1.18
Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem (2014) 1.17
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer (2008) 1.16
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother (2012) 1.16
Novel FAD-dependent glucose dehydrogenase for a dioxygen-insensitive glucose biosensor. Biosci Biotechnol Biochem (2006) 1.15
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res (2006) 1.15
The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther (2008) 1.15
Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci (2006) 1.14
The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.13
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther (2004) 1.12
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol (2008) 1.11
Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.11
Preoperative evaluation of hepatic vasculature by three-dimensional computed tomography in patients undergoing hepatectomy. World J Surg (2006) 1.10
Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology (2008) 1.10
Next-generation peptide vaccines for advanced cancer. Cancer Sci (2012) 1.09
Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem (2010) 1.09
Postnatal management for prenatally diagnosed choledochal cysts. J Pediatr Surg (2004) 1.09
Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) (2008) 1.08
Restenosis and stent fracture following sirolimus-eluting stent (SES) implantation. Circ J (2007) 1.08
UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene (2005) 1.08
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep (2010) 1.07
Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg (2005) 1.07
Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res (2002) 1.07
Effects of fluid flow on elution of hydrophilic modifier from dialysis membrane surfaces. J Artif Organs (2008) 1.06
Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol (2008) 1.06
Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas (2011) 1.06
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05
Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology (2004) 1.04
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Alveolar echinococcosis: MR findings in the liver. Radiology (2003) 1.04
Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg (2003) 1.03
BlotGlycoABCTM, an integrated glycoblotting technique for rapid and large scale clinical glycomics. Mol Cell Proteomics (2007) 1.03
A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation (2007) 1.03
N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer (2007) 1.03
Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol (2012) 1.03